El presente reporte de casos muestra los resultados del empleo de bexaroteno en dosis bajas más fototerapia o Interferon alfa 9 millones en el tratamiento del linfoma cutáneo de células T (LCCT). Ocho pacientes fueron tratados, cinco fueron Micosis fungoides, dos Linfoma Epidermotrópico CD8 agresivo y uno fue un Síndrome Sézary. La respuesta global fue del 62.5% (5/8) y la duración media de respuesta fue de 20 meses. El bexaroteno en dosis bajas en combinación a fototerapia o Interferon alfa 2a puede ser efectivo en el tratamiento del LCCT.

Introduction: Bexarotene is a rexinoid compound that is approved for use in the therapy for early and advanced stage cutaneous T-cell lymphoma (CTCL).Clinical Cases: We present in this report the results of the use of low-dose bexarotene plus phototherapy or alpha-interferon, nine million units, in the treatment of CTCL. Eight patients were treated, five had mycosis fungoides, two had CD-8 epidermothropic aggressive lymphoma. The overall response rate was 62.5% (5/8), and the mean duration of response was 20 months. Low-dose bexarotene combined with phototherapy or alpha-interferon may be effective in the treatment of CTCL.

Introduction: Bexarotene is a rexinoid compound that is approved for use in the therapy for early and advanced stage cutaneous T-cell lymphoma (CTCL).Clinical Cases: We present in this report the results of the use of low-dose bexarotene plus phototherapy or alpha-interferon, nine million units, in the treatment of CTCL. Eight patients were treated, five had mycosis fungoides, two had CD-8 epidermothropic aggressive lymphoma. The overall response rate was 62.5% (5/8), and the mean duration of response was 20 months. Low-dose bexarotene combined with phototherapy or alpha-interferon may be effective in the treatment of CTCL.

Background: Several reviews and guidelines on the management of Mycosis Fungoides (MF) and Sézary syndrome (SS) have been published; however, treatment strategies for patients with MF/SS vary from institution to institution and among countries. There are few phase III trials to support treatment decisions for MF/SS and treatment is often determined by institutional experience. Objetive: In order to summarise the available evidence and review best practices, Peruvian Consensus met in September 2004 to establish guidelines for the diagnosis and treatment of MF/SS. Results:This article reviews hystopatologic, clinic and therapeutic criteria of MF/SS.

Background: Several reviews and guidelines on the management of Mycosis Fungoides (MF) and Sézary syndrome (SS) have been published; however, treatment strategies for patients with MF/SS vary from institution to institution and among countries. There are few phase III trials to support treatment decisions for MF/SS and treatment is often determined by institutional experience. Objetive: In order to summarise the available evidence and review best practices, Peruvian Consensus met in September 2004 to establish guidelines for the diagnosis and treatment of MF/SS. Results:This article reviews hystopatologic, clinic and therapeutic criteria of MF/SS.